CoapTech Revenue and Competitors

Location

$10.6M

Total Funding

Estimated Revenue & Valuation

  • CoapTech's estimated annual revenue is currently $4M per year.(i)
  • CoapTech's estimated revenue per employee is $125,500
  • CoapTech's total funding is $10.6M.

Employee Data

  • CoapTech has 32 Employees.(i)
  • CoapTech grew their employee count by 45% last year.

CoapTech's People

NameTitleEmail/Phone
1
Founder, CMOReveal Email/Phone
2
Co-Founder, CEOReveal Email/Phone
3
SVP EngineeringReveal Email/Phone
4
VP Strategic AccountsReveal Email/Phone
5
Director Clinical ResearchReveal Email/Phone
6
Director Clinical EngagementReveal Email/Phone
7
Marketing Manager/Operations SpecialistReveal Email/Phone
8
Senior Product EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$18.6M7432%N/AN/A
#2
$7.8M31-9%N/AN/A
#3
$4M167%N/AN/A
#4
$4M167%N/AN/A
#5
$6M244%N/AN/A
#6
$19.1M7629%N/AN/A
#7
$7.8M1633%$10.9MN/A
#8
$5M20N/AN/AN/A
#9
$27.6M11010%N/AN/A
#10
$4M160%N/AN/A
Add Company

What Is CoapTech?

CoapTech is bringing a series of breakthrough medical devices to worldwide markets, leveraging a patented, disruptive platform technology called the Point-of-care Ultrasound Magnet Aligned (PUMA) System. The PUMA Platform will disrupt multiple medical procedures, reducing health care costs, and improving efficiency, safety, quality, patient experience, and access to services around the globe. Invented by Dr. Steven Tropello, a Johns Hopkins-trained critical care physician, the PUMA System enables diagnostic, interventional and therapeutic procedures in hollow organs. The system combines magnetic attraction for device placement guidance, and ubiquitous, low-cost, point-of-care ultrasound for visualization in hollow cavities. Our lead device, the PUMA-G, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of Gastrostomy (feeding) tubes. PUMA-G enables a point-of-care (i.e. bedside, as opposed to operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. By eliminating specialty suites and specialist consultants, PUMA-G will save hospitals money and improve efficiency and safety for this common procedure. PUMA-G has been validated in human anatomy, and has a streamlined regulatory pathway based on FDA presubmission feedback.

keywords:N/A

$10.6M

Total Funding

32

Number of Employees

$4M

Revenue (est)

45%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CoapTech News

2022-03-22 - CoapTech prepares clinical trials for its ultrasound-based device

The company's device uses ultrasound for feeding tube placement and hopes to reduce risk of radiation in young patients. ... CoapTech team members...

2022-03-22 - CoapTech Announces IDE Approval from FDA to Initiate ...

CoapTech Announces IDE Approval from FDA to Initiate Clinical Trial for its PUMA-G Peds System for Pediatric Gastrostomy...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.4M320%N/A
#2
N/A3210%N/A
#3
$8.3M320%N/A
#4
$5M323%N/A
#5
$5.6M32-48%N/A